Ask about this productRelated genes to: DYNC1LI1 antibody
- Gene:
- DYNC1LI1 NIH gene
- Name:
- dynein cytoplasmic 1 light intermediate chain 1
- Previous symbol:
- DNCLI1
- Synonyms:
- -
- Chromosome:
- 3p22.3
- Locus Type:
- gene with protein product
- Date approved:
- 2002-06-12
- Date modifiied:
- 2016-10-05
Related products to: DYNC1LI1 antibody
Related articles to: DYNC1LI1 antibody
- Neural crest (NC) cells are dynamic embryonic stem cells that undergo an epithelial-to-mesenchymal transition (EMT) and alter their cell states from tightly adherent to migratory and invasive during early development. While EMT transcriptional programs are well characterized, how cytoskeletal architecture is developmentally patterned across EMT states remains poorly understood. Here, we present a spatial and temporal atlas of α- and β-tubulin isotype gene expression during NC EMT in the chick embryo. Single cell RNA-sequencing reveals diversity in tubulin isotype gene expression from ubiquitous (, ) to cell type specific (, ). In addition, we identified novel enrichment of several tubulin isotypes in NC and NC-associated clusters (, , ). Using fluorescent hybridization chain reaction (HCR), we focus on NC EMT and migration states to validate and spatially resolve these expression patterns. Additional characterization in differentiated cells reveals tubulin gene expression in specific neuronal and myogenic populations. We further identify expression of the microtubule motor genes and within neural tube and NC populations, suggesting coordinated regulation of microtubule composition and cargo transport capacity. Together, these data establish that vertebrate NC EMT is accompanied by systematic reprogramming of tubulin gene expression and provide a developmental resource for investigating cytoskeletal control of cell state transitions. - Source: PubMed
Publication date: 2026/03/06
Echeverria Camilo VRamarapu RaneeshBatista Nancy DiazLopez Christian TorresMendez JoanneRogers Crystal D - Remission from pre-diabetes and type 2 diabetes (T2D) is frequently observed immediately after a duodenal/jejunal bypass. This demonstrates the reversibility of T2D and involvement of the proximal small intestine in T2D pathology. This study investigates the role of the duodenum in the pathophysiology of T2D, in line with the hypothesis, that exclusion of duodenum/jejunum in T2D (for example, in RYGB surgery) prevents release of unidentified factors that impair insulin sensitivity, leading to T2D remission. The study aimed at identifying novel protein therapeutic targets in human duodenum in T2D and clarifying aetiology. - Source: PubMed
Publication date: 2026/03/16
Alves Beatriz D GMonteiro PaulaMartins Pedro CBraga JoséMatthiesen RuneVideira José Flávio GMollet Inês G - : Colorectal cancer (CRC) is a major contributor to cancer-related deaths worldwide. While existing screening tools are effective, their high cost and limited availability restrict widespread adoption, particularly in low- and middle-income settings. The identification of affordable, non-invasive biomarkers is therefore critical to improve early CRC detection and survival outcomes. : A systematic literature search was performed through PubMed, ScienceDirect, Medline, ISI Web of Knowledge, and Google Scholar to identify studies reporting stool- and blood-based biomarkers for CRC detection. Data were extracted using a standardized template, including study details, specimen type, detection method, and diagnostic performance parameters such as sensitivity and specificity. : DNA methylation biomarkers demonstrated high diagnostic potential. and achieved a combined stool sensitivity of 91.35%. Other methylation markers, including , , and , showed a composite sensitivity of 82.7%. Plasma-based methylation markers such as , , and reported sensitivities ranging from 18-47% and specificities of 93-99%. Hypermethylation of and achieved 81.3% sensitivity in CRC and precursor lesions. ( and ) were elevated in CRC patients, with stool yielding 72.2% sensitivity and 95% specificity. A stool gene panel (, , , ) reached 96.6% sensitivity and 89.7% specificity, while a methylation-based panel (, , , , , , ) achieved 90.7% sensitivity. MicroRNAs (, , , ) showed excellent diagnostic performance, with sensitivities exceeding 96% and specificities above 75%. : DNA methylation and microRNA biomarkers hold strong promises for non-invasive CRC screening. Multi-marker panels demonstrate superior diagnostic accuracy and may provide a cost-effective, scalable approach for early CRC detection in resource-limited settings. - Source: PubMed
Publication date: 2025/12/27
Hallom PumelelaNaidoo PragalathanSenzani SibusisoKader Sayed SMkhize-Kwitshana Zilungile L - Dynein cytoplasmic 1 light intermediate chain 1 (LIC1, DYNC1LI1) is a core subunit of the dynein motor complex. The LIC1 subunit also interacts with various cargo adaptors to regulate Rab-mediated endosomal recycling and lysosomal degradation. Defects in this gene are predicted to alter dynein motor function, Rab binding capabilities, and cytoplasmic cargo trafficking. Here, we have identified a dync1li1 zebrafish mutant, harboring a premature stop codon at the exon 12/13 splice acceptor site, that displays increased angiogenesis. In vitro, LIC1-deficient human endothelial cells display increases in cell surface levels of the pro-angiogenic receptor VEGFR2, SRC phosphorylation, and Rab11-mediated endosomal recycling. In vivo, endothelial-specific expression of constitutively active Rab11a leads to excessive angiogenesis, similar to the dync1li1 mutants. Increased angiogenesis is also evident in zebrafish harboring mutations in rilpl1/2, the adaptor proteins that promote Rab docking to Lic1 to mediate lysosomal targeting. These findings suggest that LIC1 and the Rab-adaptor proteins RILPL1 and 2 restrict angiogenesis by promoting degradation of VEGFR2-containing recycling endosomes. Disruption of LIC1- and RILPL1/2-mediated lysosomal targeting increases Rab11-mediated recycling endosome activity, promoting excessive SRC signaling and angiogenesis. - Source: PubMed
Publication date: 2024/10/02
Johnson DymonnColijn SarahRichee JahmieraYano JosephBurns MargaretDavis Andrew EPham Van NSaric AmraJain AkanshaYin YingCastranova DanielMelani MarianaFujita MisatoGrainger StephanieBonifacino Juan SWeinstein Brant MStratman Amber N - : Liver hepatocellular carcinoma (LIHC) is one of the leading causes of cancer-related death. The prognostic outcomes of advanced LIHC patients are poor. Hence, reliable prognostic biomarkers for LIHC are urgently needed. : Data for vesicle-mediated transport-related genes (VMTRGs) were profiled from 338 LIHC and 50 normal tissue samples downloaded from The Cancer Genome Atlas (TCGA). Univariate Cox regression and Least Absolute Shrinkage and Selection Operator (LASSO) regression analyses were performed to construct and optimize the prognostic risk model. Five GEO datasets were used to validate the risk model. The roles of the differentially expressed genes (DEGs) were investigated via Kyoto Encyclopedia of Genes and Genomes (KEGG) and Gene Ontology (GO) enrichment analyses. Differences in immune cell infiltration between the high- and low-risk groups were evaluated using five algorithms. The "pRRophetic" was used to calculate the anticancer drug sensitivity of the two groups. Transwell and wound healing assays were performed to assess the role of GDP dissociation inhibitor 2 (GDI2) on LIHC cells. : A total of 166 prognosis-associated VMTRGs were identified, and VMTRGs-based risk model was constructed for the prognosis of LIHC patients. Four VMTRGs (GDI2, DYNC1LI1, KIF2C, and RAB32) constitute the principal components of the risk model associated with the clinical outcomes of LIHC. Tumor stage and risk score were extracted as the main prognostic indicators for LIHC patients. The VMTRGs-based risk model was significantly associated with immune responses and high expression of immune checkpoint molecules. High-risk patients were less sensitive to most chemotherapeutic drugs but benefited from immunotherapies. cellular assays revealed that GDI2 significantly promoted the growth and migration of LIHC cells. : A VMTRGs-based risk model was constructed to predict the prognosis of LIHC patients effectively. This risk model was closely associated with the immune infiltration microenvironment. The four key VMTRGs are powerful prognostic biomarkers and therapeutic targets for LIHC. - Source: PubMed
Publication date: 2024/05/13
Ye ZhiyueWang YangYuan RuixinDing RanHou YaxinQian LuomengZhang Sihe